Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma II

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE213518 | GEO | 2023/05/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma II

Project description:A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma II

| PRJNA881265 | ENA

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [RNA-seq]

Project description:We screened HCC organoids to identify a CTNNB1-mutant HCC selective small molecule (WNTinib), with MOA depending on reactivation of cytoplasmic EZH2, leading to its nuclear translocation and selective transcriptional block of WNT targets We then performed gene expression profiling analysis using data obtained from RNA-seq of 2 genetically different organoids at 3 time points.

2023-05-03 | GSE213517 | GEO

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [Cut&Run]

2023-05-03 | GSE213515 | GEO

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [RNA-seq]

Project description:A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [RNA-seq]

| PRJNA881285 | ENA

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [Cut&Run]

Project description:A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [Cut&Run]

| PRJNA881282 | ENA

Hepatocellular Carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-12-10 | E-GEOD-57958 | biostudies-arrayexpress

Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma.

Project description:There is an urgent need to understand the molecular signaling pathways that drive or mediate the development of hepatocellular carcinoma (HCC). The focal adhesion kinase (FAK) gene protein tyrosine kinase 2 is amplified in 16.4% of The Cancer Genome Atlas HCC specimens, and its amplification leads to increased FAK mRNA expression. It is not known whether the overexpression of FAK alone is sufficient to induce HCC or whether it must cooperate in some ways with other oncogenes. In this study, we found that 34.8% of human HCC samples with FAK amplification also show β-catenin mutations, suggesting a co-occurrence of FAK overexpression and β-catenin mutations in HCC. We overexpressed FAK alone, constitutively active forms of β-catenin (CAT) alone, or a combination of FAK and CAT in the livers of C57/BL6 mice. We found that overexpression of both FAK and CAT, but neither FAK nor CAT alone, in mouse livers was sufficient to lead to tumorigenesis. We further demonstrated that FAK's kinase activity is required for FAK/CAT-induced tumorigenesis. Furthermore, we performed RNA-sequencing analysis to identify the genes/signaling pathways regulated by FAK, CAT, or FAK/CAT. We found that FAK overexpression dramatically enhances binding of β-catenin to the promoter of androgen receptor (AR), which leads to increased expression of AR in mouse livers. Moreover, ASC-J9, an AR degradation enhancer, suppressed FAK/CAT-induced HCC formation. Conclusion: FAK overexpression and β-catenin mutations often co-occur in human HCC tissues. Co-overexpression of FAK and CAT leads to HCC formation in mice through increased expression of AR; this mouse model may be useful for further studies of the molecular mechanisms in the pathogenesis of HCC and could lead to the identification of therapeutic targets.

| S-EPMC6819211 | biostudies-literature

Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.

Project description:We previously identified Aurora B kinase as the only independent factor predictive of the aggressive recurrence of hepatocellular carcinoma (HCC). In this preclinical study, JNJ-28841072, a novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor, was evaluated for treatment of HCC. In vitro and in vivo effects of JNJ-28841072 were analyzed using human HCC cell cultures and xenograft models. An orthotopic liver xenograft model was used for the pharmacobiological effects on Aurora kinase and vascularization in hepatic tumors. JNJ-28841072 suppressed in vitro phosphorylation of histone H3 with induction of cell polyploidy and death in a dose-dependent manner (IC50 = 0.8-1.2 μM). In s.c. human HCC xenografts, remarkable inhibition of tumor growth was observed after JNJ-28841072 treatment (P = 0.0005). In orthotopic liver xenografts, the treatment with JNJ-28841072 significantly suppressed in vivo phosphorylation of histone H3 (P = 0.0008), vessel formation (P = 0.018), normoxic area (P = 0.0001), and hepatoma growth (P = 0.038). Our preclinical studies indicate that JNJ-28841072 is a promising novel therapeutic approach for the treatment of HCC. It might be worthy of evaluation in further studies.

| S-EPMC4556391 | biostudies-literature

Hepatocellular Carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2014-12-10 | GSE57958 | GEO

Tyrosine Kinase Inhibitor Cardiotoxicity

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-11-02 | GSE89411 | GEO